Alnylam Pharmaceuticals, Inc. (ALNY) vs Centene Corp. (CNC)
A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and Centene Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 29, 2026. Differences are shown without an overall score or investment verdict.
ALNY
Alnylam Pharmaceuticals, Inc.
$237.10HealthcareAt close: Aug 28, 2026, 4:00 PM ET
CNC
Centene Corp.
$64.75HealthcareAt close: Aug 28, 2026, 4:00 PM ET
Total return — ALNY vs CNC
growth of $100 · dividends reinvested · last 10yALNY +231.3% (+12.7%/yr)CNC +84.8% (+6.3%/yr)ALNY compounded faster over this window
ALNY CNC
ALNY vs CNC: by the numbers
- •CNC is the larger company ($31.99B vs $31.73B market cap).
- •ALNY is profitable (16.82% net margin) while CNC runs a net loss (-2.63%).
- •ALNY grew revenue faster over the past five years (47.53% vs 10.35% CAGR).
Metrics side by side
Valuation
| Metric | ALNY | CNC |
|---|---|---|
| P/E ratio | 40.05 | N/A |
| Forward P/E | 36.43 | 13.48 |
| P/S ratio | 6.82 | 0.17 |
| P/B ratio | 24.21 | 1.43 |
| EV / EBITDA | 30.68 | N/A |
| FCF yield | 1.66% | 27.86% |
Profitability
| Metric | ALNY | CNC |
|---|---|---|
| Gross margin | 79.72% | 16.13% |
| Operating margin | 20.81% | -2.82% |
| Net margin | 16.82% | -2.63% |
| ROE | 59.67% | -22.60% |
| ROIC | 24.71% | -12.90% |
Growth (annualized)
| Metric | ALNY | CNC |
|---|---|---|
| Revenue CAGR (5Y) | 47.53% | 10.35% |
| FCF CAGR (5Y) | N/A | -1.39% |
| Total return CAGR (5Y) | 3.06% | 0.24% |
Frequently asked
- Which has grown faster, ALNY or CNC?
- Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus CNC at 10.35%.
- Is ALNY or CNC more profitable?
- ALNY runs the higher net margin — ALNY at 16.82% versus CNC at -2.63%.
- How have ALNY and CNC total returns compared?
- Over the past 10 years, ALNY delivered 12.84% and CNC delivered 6.70% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Alnylam Pharmaceuticals P/E ratioAlnylam Pharmaceuticals ROECentene ROEAlnylam Pharmaceuticals operating marginCentene operating marginAlnylam Pharmaceuticals revenue growthCentene revenue growthAlnylam Pharmaceuticals free cash flowCentene free cash flow
Alnylam Pharmaceuticals & Centene appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 29, 2026.